secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0001628280-26-019995
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma wins FDA approval for IMCIVREE in acquired hypothalamic obesity; Phase 3 shows -18.4% BMI reduction
--------------------------------------------------------------------------------

- FDA approved IMCIVREE (setmelanotide) for acquired HO in adults and children 4+; first approved therapy for this indication.
- Phase 3 TRANSCEND: setmelanotide (-15.8% BMI) vs placebo (+2.6%) at 52 weeks; placebo-adjusted -18.4% (p<0.0001).
- Most common AEs (>20%): skin hyperpigmentation, nausea, vomiting, headache.
- Rhythm estimates ~10,000 U.S. patients with acquired HO; drug available immediately.
- IMCIVREE already approved for BBS and monogenic obesity due to POMC/PCSK1/LEPR deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/0001628280-26-019995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/rytm-20260319.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-019995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer